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Background: Newborn screening (NBS) for Cystic Fibrosis (CF) has been introduced in many countries, but there is no ideal protocol suitable for
all countries. This retrospective study was conducted to evaluate whether the planned two step CF NBS with immunoreactive trypsinogen (IRT)
and 7 CFTR mutations would have detected all clinically diagnosed children with CF in Switzerland.
Methods: IRT was measured using AutoDELFIA Neonatal IRT-Kit in stored NBS cards.
Results: Between 2006 and 2009, 66 children with CF were reported, 4 of which were excluded for various reasons (born in another country, NBS
at 6 months, no informed consent). 98% (61/62) had signiﬁcantly higher IRT compared to matched control group. There was one false negative
IRT result in an asymptomatic child with atypical CF (normal pancreatic function and sweat test).
Conclusions: All children but one with atypical CF would have been detected with the planned two step protocol.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: New born screening; Cystic ﬁbrosis; Immunoreactive trypsinogen1. Introduction
Cystic fibrosis (CF) is the most common life-shortening,
childhood-onset autosomal recessive inherited disorder in
white populations with a frequency of about 1 in 2500 live-
births [1,2]. Prognosis has significantly improved with early
and aggressive treatment of chest infection and a holistic⁎ Corresponding author at: Paediatric Pulmonology, Children's Hospital,
CH-9006 St. Gallen, Switzerland. Tel: +41 71 243 71 11; fax: +41 71 243 76 99.
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doi:10.1016/j.jcf.2012.01.001approach to management with nutritional well being [3]. Life
expectancy of patients with CF has been greatly increased
over past decades and the predicted median survival for babies
born in the 21st century is now more than 50 years [4].
In 1979, the development of a test to measure immunoreac-
tive trypsinogen (IRT) in dried blood spots made universal
newborn screening (NBS) for CF feasible [5]. The first nation-
wide NBS for CF began in New Zealand and New South Wales
(Australia) in 1981 [6]. With the detection of the CF transmem-
brane regulator (CFTR) gene in 1989, a two step screening was
introduced with measurement of IRT being the first and the
confirmation of a CFTR mutation being the second step
[7–9]. Since then, many European regions and countries haveby Elsevier B.V. All rights reserved.
333J. Barben et al. / Journal of Cystic Fibrosis 11 (2012) 332–336introduced NBS for CF, however, more than 25 screening pro-
grams have been developed, with quite marked variation in pro-
tocol design [7].
In 2004, the Centers for Disease Control (CDC) have pub-
lished a report on evaluation of benefits and risks of CF new-
born screening, and the authors have stated that the states
should consider the magnitude of benefits and costs and the
need to minimize risks through careful planning and implemen-
tation, including ongoing collection and evaluation of outcome
data [8]. As a consequence, guidelines for NBS for CF were
published by the American Cystic Fibrosis Foundation (CFF)
in 2007, and by the European Cystic Fibrosis Society (ECFS)
in 2009 [10,11]. Given the wide geographic, ethnic, and eco-
nomic variations, complete harmonisation of protocols is not
appropriate, and every country has to evaluate and optimise
its own NBS for CF.
In Switzerland, NBS was introduced for the detection of
Phenylketonuria (PKU) in 1965, using a dried blood spot
(Guthrie test) on the 4th day of life. In the meantime, five
other diseases were added to the NBS, including galactosaemia,
congenital hypothyroidism, biotinidase deficiency, congenital
adrenal hyperplasia (CAH), and MCAD deficiency. From 1st
January 2006, newborn screening was centralised, and since
then, around 80,000 tests per year were performed by the
Swiss Newborn Screening Laboratory (SNSL) at the University
Children's Hospital in Zürich.
In 2007, the Swiss Working Group for Cystic Fibrosis
(SWGCF) has joined forces with the SNSL to form a task
force for the introduction of NBS for CF in Switzerland. The
planned NBS for CF in Switzerland includes an IRT/DNA al-
gorithm (Fig. 1). If IRT is elevated (N99th percentile) a screen-
ing test with the seven most common CFTR mutations in
Switzerland (F508del, 3905insT, G542X, R553X, W1282X,Report: CF not
suspected 
< 99th percentile
Measurement of IRT in dried blood spot
(4th day of life) 
Referral to
CF center
One or two
CF mutations 
Report: CF not 
suspected
Referral to
CF center 
No CF mutation
DNA analysis
(7 mutations)
IRT on 2nd
blood spot
99th percentile
2nd heel blood
sample 
< 99 percentile99th percentile
Definition of abbreviations: 
IRT = immunoreactive trypsinogen; CF = cystic fibrosis 
Fig. 1. Flow chart of the planned newborn screening programme in Switzerland.-
Definition of abbreviations:IRT=immunoreactive trypsinogen; CF=cystic fibrosis.1717-1 GNA, N1303K) [12] will be used to confirm the
suspicion.
In this study, we aimed to evaluate whether the planned two
step NBS for CF based on IRT and the seven most common
CFTR mutations in Switzerland would have retrospectively
detected more than 95% of children with a clinical diagnosis
of CF.
2. Materials and methods
2.1. Study design and subjects
A questionnaire was mailed to all Swiss CF centres to collect
all names of children who were diagnosed with CF based on
clinical symptoms and two positive sweat tests (or confirmation
with genetic test) and born between 1st January 2006 and 31st
December 2009. The day of birth and the initials of all children
were sent to the national newborn screening laboratory at the
University Children's Hospital in Zürich. Subsequently, all rou-
tine NBS cards from the 4th day of life of these children were
retrieved, and IRT was measured. In addition, routine NBS
cards of matched controls (8–10 healthy children from the
same day) were also tested. The local ethics committee ap-
proved the study and all parents had to give written informed
consent.
2.2. IRT measurements
IRT was measured in dried blood spot using the AutoDEL-
FIA Neonatal IRT-Kit (PerkinElmer Wallac, Turku, Finnland)
[13–15]. AutoDELFIA is an automatic immunoassay system,
which performs all sample and reagent handling as well as all
assay stages automatically. The assay is based on the direct
sandwich technique in which two monoclonal antibodies bind
to different epitopes on the target molecule. The enhanced sig-
nal is measured with high analytical sensitivity using time-
resolved fluorometry; the analytical sensitivity of the assay is
better than 0.5 ng/ml blood. Intra-assay imprecision for the
clinically relevant area is close to 9%. All calibrators and con-
trols are lot-specific to ensure that every lot is of the same level.
2.3. CF-gene mutation analysis
The seven most common CFTR mutations in Switzerland
were determined as described earlier [16]. In brief, this assay
is based on DNA amplification of four fragments containing
the mutations (F508del, 3905insT, G542X, R553X, W1282X,
1717-1 GNA, and N1303K) by PCR, followed by hybridiza-
tion with short, allele-specific oligonucleotide probes labeled
with europium, terbium, or samarium chelates. In addition,
this Swiss panel was compared with two commercially avail-
able CF-gene mutation kits: INFINITI® CFTR-15 Assay
(AutoGenomics, Vista, USA), which tests for 15 CFTR muta-
tions, and LUMINEX xTAG® Cystic Fibrosis 39 kit v2 (Lumi-
nex Corporation, Austin, USA), which tests for 39 CFTR
mutations. Both these assays are based on a Multiplex PCR am-
plification of DNA, followed by fluorescent label incorporation
Table 2
CFTR mutations measured retrospectively in NBS cards of clinically diagnosed
children with CF (N=63).
CFTR mutations Alleles found Percentage of total Homozygous (n)
F508del a 86 68.2 30
3905insT a 4 3.2 1
a
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tion reaction the Infinity System uses hybridization of the
ASPE primers to a microarray. In the Luminex System the
ASPE product is hybridized to beads. Result evaluation in
both systems is fully automated using specifically designed
software.G542X 3 2.4 –
R553X a 3 2.4 1
W1282X a 2 1.6 –
1717-1 GNA a 2 1.6 –
N1303K a 0 0.0 –
S549R 3 2.4 1
Q525X 3 2.4 –
Y1092X 2 1.6 –
3120+1 GNA b 2 1.6 1
2347delG 2 1.6 –
2176insC 1 0.8 –
3659delC 1 0.8 –
3359delCTCTG 1 0.8 –
W1089X 1 0.8 –
711+1 GNT 1 0.8 –
D1152H 1 0.8 –
G1244E 1 0.8 –
R1066C 1 0.8 –
R31C 1 0.8 –
R347P 1 0.8 –
R74W 1 0.8 –
S945L 1 0.8 –
T501I 1 0.8 –
K68X 1 0.8 –
Total 126 100.0% 34
a Seven most common CF-gene mutations in Switzerland (“Swiss
panel”) =79.4% (100/126) of alleles.
b Child with NBS at 6 months of age (see text).3. Results
In total, 66 children with clinically diagnosed CF were
reported from the CF centres. The median time of the clinical
diagnosis of these children was 7.0 months (range: 0–48.2).
From 65 we received permission from the parents to analyse
their NBS card. In three children, IRT result at birth was not
available, as all three children were born in a foreign country.
One of them had NBS at the age of 6 months because of unclear
illness. This child from Congo was later diagnosed with CF
(3120+1 GNA homozygous) and the IRT value at the age of
six months was 24 ng/ml. Of the remaining 62 children with
available NBS cards on the 4th day of life, 41 had IRT-values
above 60 ng/ml, 20 had IRT-values that were higher (all
above 32 ng/ml) compared to IRT-measurements from NBS
cards of matched controls, stored for the same time period
(Table 1).
One child had a normal IRT value, even compared to
matched controls (9.72 vs. 9.68 ng/ml). This child was diag-
nosed with atypical CF in the first week of life using molecular
diagnostics (F508 del/R31C) as both parents were known het-
erozygous CF carriers. The child has normal pancreatic func-
tion and would have been missed in the proposed algorithm
as the IRT was identical to the control group and the sweat
test was normal (sweat chloride=15 mmol/l). At the age of
4 years, this child was still without any symptoms.
The Swiss panel of 7 CFTR mutations would have detected
79.4% (100/126) of all mutations out of the available 63 NBS
cards (Table 2): 40 (63.5%) children with two mutations and
20 (31.7%) with one mutation. Three (4.8%) children did not
have any of these 7 CFTR mutations. Using a commercial test
kit with 15 CFTR mutations (INFINITI), no additional child
would have been detected. Using LUMINEX with 39 CFTR
mutations, two additional children (CFTR mutation 711+
1 GNT and 3120+1 GNA) would have been detected in the
first step of our algorithm, leaving one (instead of three), who
would have needed a second blood sample. At least oneTable 1
Range of IRT-values [ng/mL] measured retrospectively in NBS cards of clini-
cally diagnosed children with CF (N=62) and in NBS cards of matched
controls.
Year Patients with CF IRT (range) in CF
Patients [ng/mL]
IRT (range) in matched
controls [ng/mL]
2006 16 9.7 a–117 2.2–29.5
2007 19 32.0–259 2.2–31.6
2008 11 37.7–176 3.7–33.8
2009 16 48.2–160 3.5–43.9
a IRT value in child with atypical CF (see text).F508del mutation was found in 88.9% (56/63) of these
children.4. Discussion
This retrospective study suggests that the planned algorithm
for the NBS for CF, with IRT as the first tier and the seven most
common CFTR mutations as a second tier (Fig. 1), would have
detected 98% (61/62) of all clinically diagnosed children with
CF in Switzerland.
In the last decades, NBS for CF has been implemented in
many countries including New Zealand, Australia, Austria,
France, Poland, the United Kingdom, Russia and the United
States. However, there is a very broad spectrum of screening
protocols [7,10]. As the American CF Foundation has stated
in their guidelines for implementation of NBS for CF, a screen-
ing algorithm depends on program resources and goals includ-
ing mechanisms available for sample collection, regional
demographics, the spectrum of cystic fibrosis disease pheno-
type wanted to be detected, and acceptable failure rates of the
screen in every country [11]. In 2007, the SWGCF planned to
implement a NBS for CF with two aims: First to detect at
least 95% of all children with CF, and second, not to compro-
mise the established NBS, which has an excellent acceptance
in Switzerland with only a handful of test refusal each year.
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2007, every genetic test including any new screening test has
to be approved by the Federal Office of Public Health
(FOPH). Among others, the FOPH required a retrospective
study as a proof that the planned algorithm is functioning. Al-
though the new law requires written informed consent for ge-
netic tests, oral informed consent for screening tests is still
allowed thus not compromising this currently well established
practice of NBS in Switzerland. After delivery, all families
get an information brochure explaining NBS, the dried blood
spot test and the currently six screened diseases; if they do
not actively disagree, their baby will be tested. According to
the current law regulating genetic testing in Switzerland, a writ-
ten informed consent for genetic tests is only mandatory for di-
agnostic tests, which will be carried out in the CF centres.
With a detection rate of 98% (61/62), the planned algorithm
for the NBS for CF seems to be adequate for our country. In
fact, the detection rate in our study was 100% (61/61), if one
considers that recognising children with atypical CF is not the
primary aim of a newborn screening programme.
The selected seven CF-gene mutations were adequate to dis-
cover nearly all CF-patients in the first step of our algorithm of
the NBS for CF in Switzerland. Only three children would have
been missed in the Swiss panel, and would have had a second
NBS test due to the elevated first IRT measurement. With INFI-
NITI (15 CFTR mutations) no additional CFTR mutations
would have been identified, and with LUMINEX (39 CFTR
mutations) only two additional CFTR mutations would have
been detected. This means that with the determination of addi-
tional 32 CFTR mutations only two recalls (second heel blood
sample) could have been prevented. On the other hand, the
main goal is to detect the severe classical cases of CF and not
the mild cases (atypical CF) with late symptomatic onset [17].
Therefore we created an algorithm similar to the United King-
dom, however, with a panel of 7 CFTR mutations instead of
30 mutations. In the future, this panel has to be observed very
carefully and adjusted if necessary, as Switzerland has one of
the highest percentage of immigrants compared to the number
of inhabitants in Europe. To ensure that we do not miss children
from other countries with classical CF due to mutations uncom-
mon in Switzerland, we have created a safety net in our algo-
rithm with the possibility to detect such children with an
elevated IRT value on the second heel blood sample (Fig. 1).
This would have been the case with the immigrated child from
Congo which was homozygous for 3120+1 GNA, and was ex-
cluded from our study as it had no IRT measurement at birth.
It was not the aim of our retrospective study to determine the
absolute IRT cut-off for our planned NBS programme which is
determined by the fairly normal distribution in the normal pop-
ulation. It is well known, that IRT levels decline with time of
sample storage [18]. Therefore, we have used matched controls
in our study, and all children with classical CF had an elevated
IRT in comparison with these controls. As a consequence of
our retrospective study, we have decided to introduce NBS
for CF on the 1st January 2011 with a cut-off for IRT on the
99th percentile (suggested IRT value from the literature:
60 ng/ml). In a test run in December 2010, we have realisedthat the corresponding IRT value for the 99th percentile was
lower (45 ng/ml). Within the first 4 months of our pilot project,
we have adjusted the IRT threshold to 50 ng/ml (99.5th percen-
tile) to minimise the need for a second NBS test, as we have not
found a child with CF with an IRT value b50 ng/ml. For the
safety net, we decided to use an elevated IRT value above the
99th percentile, when no CFTR mutation has been found. If
the IRT value in the second heel blood sample is again above
the 99th percentile and the first IRT was above the 99.5 percen-
tile, the child is also referred to a CF centre for a sweat test.
In conclusion, this retrospective study provided a solid evi-
dence base to support implementation of the Swiss NBS pro-
gramme with a two step protocol.
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